TG Therapeutics (TGTX) Q2 2026 earnings review
BRIUMVI Commercial Juggernaut Meets Manufacturing Price Tag
TG Therapeutics delivered an exceptional quarter commercially and clinically, but profitability took a temporary back seat. U.S. BRIUMVI sales accelerated 64% YoY to $227.7 million, prompting management to raise full-year guidance across the board. The pipeline also achieved two major de-risking milestones: the Phase 3 ENHANCE trial successfully demonstrated bioequivalence for a single-infusion initiation, and the Phase 1 subcutaneous trial showed >60% bioavailability. However, Net Income collapsed 72% YoY to just $7.8 million. The culprit? A massive $54.6 million charge for subcutaneous manufacturing and start-up costs that dragged down operating margins. Management is actively trading short-term profits to secure a multi-billion dollar long-term franchise.
🐂 Bull Case
U.S. BRIUMVI revenue grew 64% YoY and ~17% sequentially. The drug is rapidly capturing IV anti-CD20 market share, with run-rates approaching the $1 billion annualized milestone well ahead of schedule.
Positive ENHANCE data and Subcutaneous Phase 1 bioavailability >60% effectively secure the company's lifecycle management strategy. A single IV dose and a quarterly at-home shot provide a clear roadmap to dominating the broader MS market.
🐻 Bear Case
R&D tripled YoY to $95.3 million and SG&A jumped 48% to $82.1 million. While manufacturing investments yield future margin benefits, current operating leverage is reversing.
Despite positive early data, the Phase 3 subcutaneous readout isn't due until late 2026/early 2027, placing a potential launch in 2028. Competitors like Roche and Novartis have years to entrench their at-home offerings.
⚖️ Verdict: 🟢
Bullish. The 72% drop in Net Income looks alarming on paper, but it is explicitly tied to pre-planned manufacturing investments for the subcutaneous formulation. The core IV business is printing cash and growing at a phenomenal clip.
Key Themes
Subcutaneous Formulation Validated
The Phase 1 clinical trial evaluating the subcutaneous formulation of ublituximab reported mean bioavailability greater than 60% compared to IV administration. This is a critical technological innovation milestone. PK modeling confirms this supports a quarterly dosing regimen—a highly competitive profile for the ongoing Phase 3 trial. Success here unlocks the ~35% of the anti-CD20 market that TG currently cannot access.
ENHANCE Trial Secures IV Dominance
The Phase 3 ENHANCE trial successfully met its primary endpoint, proving bioequivalence between the current Day 1/Day 15 initiation regimen and a consolidated single 600 mg infusion. Eliminating the Day 15 infusion significantly improves convenience for both patients and infusion centers, acting as a massive operational driver to steal further share from Ocrevus.
U.S. BRIUMVI Sales Acceleration
Commercial execution remains flawless. U.S. net product revenue hit $227.7 million, accelerating sequential growth (up ~17% from Q1's $194.8 million). Management's DTC campaign and expanded field force are clearly yielding a high ROI, proving that BRIUMVI is the preferred option for new patient starts in the IV space.
Operating Expenses Cannibalize Profits
The positive commercial narrative is contradicted by a steep drop in bottom-line profitability. Net income fell from $28.2 million in 25Q2 to just $7.8 million in 26Q2. This was driven by R&D expenses surging from $31.8 million to $95.3 million, largely due to a $54.6 million hit for subcutaneous manufacturing and secondary manufacturer start-up costs. While strategic, this immense cash burn requires monitoring.
SG&A Inflation Outpacing Revenue Growth
Total SG&A expense rose to $82.1 million, a 48% YoY increase compared to $55.6 million in 25Q2. Management attributes this to increased marketing, media spend, and personnel costs. While the top line grew 64%, the absolute dollar increase in SG&A shows that maintaining this growth rate requires heavy, continuous marketing investment.
Subcutaneous Timeline Leaves a Competitive Vacuum
Despite the stellar Phase 1 data, the topline Phase 3 data for the subcutaneous formulation is still not expected until year-end 2026 or early 2027. This implies a commercial launch in 2028. During this multi-year gap, competitors will continue to aggressively entrench their at-home self-administration therapies, forcing TG to fight an uphill battle upon eventual launch.
Other KPIs
A massive improvement from $199.5 million at the end of FY25. This was bolstered heavily by the $500 million Blue Owl financing facility secured in Q1 2026, combined with operational cash flow. The company's balance sheet is effectively bulletproof against current cash burn rates.
Up from $2.3 million in the prior year quarter. This segment remains a minor contributor to the overall top line, predominantly comprised of $3.6 million in royalty revenue from Neuraxpharm for ex-U.S. commercialization.
Guidance
Accelerating. Raised from the prior guidance of ~$925 million established in Q1. This implies roughly 54% YoY growth compared to FY25's $616 million, showcasing extreme confidence in H2 performance.
Accelerating. The midpoint of $897.5 million was raised from the prior range of $885 - $900 million. Given H1 2026 actuals of $422.5 million, this implies H2 2026 U.S. revenue of approximately $475 million.
Stable. The core operating expense guidance remains intact. However, management reiterated the additional ~$100 million in expenses associated with subcutaneous manufacturing. With $58.8 million already spent in H1, the drag on H2 earnings from manufacturing will likely taper slightly.
Key Questions
ENHANCE Regulatory Filing Timeline
With the Phase 3 ENHANCE trial meeting its primary endpoint, what is the exact timeline for submitting the sBLA to the FDA, and when do you anticipate the single-dose regimen to be commercially available?
Manufacturing Spend Cadence
You recorded $54.6 million in subcutaneous manufacturing expenses this quarter against a ~$100 million full-year target. Does this mean the bulk of the manufacturing margin drag is now behind us for the year, and should we expect a sharp rebound in net income in Q3?
Ex-U.S. Royalty Growth
Royalty revenue from Neuraxpharm was $3.6 million this quarter. Are you seeing the same inflection point in European adoption that you experienced in the U.S., or are structural market differences delaying ex-U.S. growth?